Literature DB >> 17253114

A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.

L Ferasin1, S Marcora.   

Abstract

Exercise testing is not commonly used in canine medicine because of several limitations. The aim of this study was to investigate the suitability of a treadmill test to measure the exercise capacity of untrained canine cardiac patients and to measure some biological parameters that might reflect the tolerance of dogs with heart failure to submaximal exercise. The exercise capacity of seven dogs with naturally occurring heart failure was evaluated before the institution of cardiac medication and 7 days after the beginning of the study. An additional re-examination was requested after 28 days. The exercise test was performed on a motorized treadmill at three different speeds (0.5 m/s, 1.0 m/s and 1.5 m/s). The following parameters were measured at the end of each stage and after 20 min recovery: heart rate, rectal temperature, glucose, lactate, aspartate aminotransferase, creatine kinase, PvO(2), PvCO(2), pH, haematocrit, bicarbonate, sodium, potassium and chloride. Serum cardiac troponin-I was also measured at the beginning of the test and at the end of the recovery period. Owners' perception reflected the ability of their dogs to exercise on the treadmill. Lactate level increased noticeably with the intensity of the exercise test, and its variation coincided with different exercise tolerance observed by the owners. Heart rate seemed to follow a similar trend in the few dogs presented in sinus rhythm. None of the remaining parameters appeared to be sensitive indicators of activity level in the dogs used in this study. The treadmill exercise test in dogs with acquired heart failure is feasible and might provide useful information for assessing individual response to cardiac medication. Lactate and heart rate seemed to reflect individual levels of exercise tolerance, although further studies are necessary to confirm the reliability and repeatability of this test.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253114     DOI: 10.1007/s11259-007-3566-7

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  18 in total

1.  How do you measure exercise capacity in chronic heart failure?

Authors:  A L Clark; J G Cleland
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

2.  Stability of the blood lactate-heart rate relationship in competitive athletes.

Authors:  C Foster; D J Fitzgerald; P Spatz
Journal:  Med Sci Sports Exerc       Date:  1999-04       Impact factor: 5.411

Review 3.  Exercise testing in the assessment of chronic congestive heart failure.

Authors:  John G Lainchbury; A Mark Richards
Journal:  Heart       Date:  2002-11       Impact factor: 5.994

4.  Evidence of myocardial injury during prolonged strenuous exercise.

Authors:  L Laslett; E Eisenbud; R Lind
Journal:  Am J Cardiol       Date:  1996-08-15       Impact factor: 2.778

Review 5.  Exercise stress testing. An overview of current guidelines.

Authors:  S A Lear; A Brozic; J N Myers; A Ignaszewski
Journal:  Sports Med       Date:  1999-05       Impact factor: 11.136

6.  Cardiac troponin T alterations in myocardium and serum of rats after stressful, prolonged intense exercise.

Authors:  Y Chen; R C Serfass; S M Mackey-Bojack; K L Kelly; J L Titus; F S Apple
Journal:  J Appl Physiol (1985)       Date:  2000-05

7.  Cardiac troponin I in acute coronary ischemic syndromes. Epidemiological and clinical correlates.

Authors:  P Lucia; A Coppola; L L Manetti; M L Sebastiani; A Colliardo; F Cerroni; C De Martinis; P M Strappini
Journal:  Int J Cardiol       Date:  2001-02       Impact factor: 4.164

8.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure.

Authors:  G H Guyatt; M J Sullivan; P J Thompson; E L Fallen; S O Pugsley; D W Taylor; L B Berman
Journal:  Can Med Assoc J       Date:  1985-04-15       Impact factor: 8.262

9.  Maximal blood lactate level acts as a major discriminant variable in exercise testing for coronary artery disease detection in men.

Authors:  J C Barthélémy; F Roche; J M Gaspoz; A Geyssant; P Minini; A Antoniadis; E Page; J E Wolf; C Wilner; K Isaaz; C Cavallaro; J R Lacour
Journal:  Circulation       Date:  1996-01-15       Impact factor: 29.690

10.  Lactate production during maximal and submaximal exercise in patients with chronic heart failure.

Authors:  K T Weber; J S Janicki
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

View more
  4 in total

Review 1.  A systematic comparison of exercise training protocols on animal models of cardiovascular capacity.

Authors:  Rui Feng; Liyang Wang; Zhonguang Li; Rong Yang; Yu Liang; Yuting Sun; Qiuxia Yu; George Ghartey-Kwansah; Yanping Sun; Yajun Wu; Wei Zhang; Xin Zhou; Mengmeng Xu; Joseph Bryant; Guifang Yan; William Isaacs; Jianjie Ma; Xuehong Xu
Journal:  Life Sci       Date:  2018-12-03       Impact factor: 5.037

2.  Reliability of an incremental exercise test to evaluate acute blood lactate, heart rate and body temperature responses in Labrador retrievers.

Authors:  Luca Ferasin; Samuele Marcora
Journal:  J Comp Physiol B       Date:  2009-05-20       Impact factor: 2.200

3.  Clinical use of submaximal treadmill exercise testing and assessments of cardiac biomarkers NT-proBNP and cTnI in dogs with presymptomatic mitral regurgitation.

Authors:  Leona Wall; Annika Mohr; Florenza Lüder Ripoli; Nayeli Schulze; Camila Duarte Penter; StephanOscar Hungerbuehler; Jan-Peter Bach; Karin Lucas; Ingo Nolte
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

4.  Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.

Authors:  Nayeli Iwanuk; Leona Wall; Ingo Nolte; Jonathan Raue; Katja Rumstedt; Anna Pilgram; Maximiliane Sehn; Karl Rohn; Jan-Peter Bach
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.